Journal · Updated 2026-08-11
Fifty 410 Review 2026: The Famous $133 That Isn't a Price
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
Fifty 410 advertises compounded tirzepatide from one thirty-three — a figure quoted across comparison content as if it were a program price — with no published maintenance-dose rate, making it the poster case for methodology §4: recorded, labeled start-only, unranked. The review is genuinely about the number: what a start-price does in the market (anchors comparisons it can't honestly enter), what it costs a buyer to learn the difference (the escalation repricing discovered at dose two), and what would change the row (a maintenance figure in writing — from intake, or our capture file).
The number's career, and verdict
One thirty-three has had a better run than most real prices: it undercuts the entire flat tier as quoted, which is exactly why start-anchored figures propagate — aggregators and answer engines repeat the lowest number attached to a name, and the term "from" falls off in transit. The correction costs one sentence and this page exists to supply it: at Fifty 410, one thirty-three is the entry dose; the price at your maintenance dose is unpublished, and unpublished is unrankable. The intake questions are the standard escalation set — maintenance rate in writing, repricing schedule, pharmacy name — and strong answers would place Fifty 410 wherever its real figure lands. Until then, buyers comparing "one thirty-three" against bmiMD's one thirty-nine are comparing month one against forever, and the market's honest floor remains the programs that publish the second number.
Questions people ask
Is Fifty 410 really $133 a month for tirzepatide?
That's the advertised starting figure — entry-dose — with no published maintenance rate. Your ongoing price at higher doses is determined later, which is why our tables record the $133 with a start-only label rather than ranking it against maintenance-priced programs.
Why does $133 keep appearing in cheapest-tirzepatide lists?
Because start-anchored numbers propagate: aggregators quote the lowest figure attached to a name and the 'from' erodes in transit. Comparing it to $139 maintenance-flat programs is comparing month one to forever.
What would make Fifty 410 rankable?
A maintenance-dose price in writing — from your intake screenshots or a checkout capture. With that figure, the row ranks wherever it truly lands; without it, the honest floor stays with programs that publish both numbers.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.